Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > Analysis
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(859)
•••
Comment by mercedesmanon Jun 08, 2024 4:33pm
83 Views
Post# 36079465

RE:RE:RE:RE:RE:Analysis

RE:RE:RE:RE:RE:Analysis

I think this is as simple as stringing together several more quarters of better than expected margins and profits to make everyone forget about fiscal 2023.

Getting annualized revenues above $30 M will help too. 

Otherwise this gets taken out for a song ( but still at a premium) as K royalties get closer and closer to reality. 

Investors today basically get huge Kinlytic upside for free .

MM 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities